Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Role of abciximab in the treatment of coronary artery disease.

Gabriel HM, Oliveira EI.

Expert Opin Biol Ther. 2006 Sep;6(9):935-42. Review.

PMID:
16918260
2.

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.

Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO).

JAMA. 2002 Nov 6;288(17):2130-5.

PMID:
12413372
4.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
5.

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.

Circulation. 2002 Sep 17;106(12):1470-6.

6.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
7.

Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.

Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ; GUSTO V Trial.

J Am Coll Cardiol. 2004 Feb 18;43(4):542-8.

8.

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.

Thromb Haemost. 1998 Dec;80(6):994-1001.

PMID:
9869173
9.
10.

Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.

Konopka A, Spychalska J, Sitkiewicz D, Zdebska E, Pilichowska I, Piotrowski W, Stepińska J.

Am J Cardiovasc Drugs. 2007;7(6):433-9.

PMID:
18076210
12.

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Bhatt DL, Topol EJ.

JAMA. 2000 Sep 27;284(12):1549-58. Review.

PMID:
11000650
13.
14.

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.

Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.

Am J Cardiol. 1999 Sep 1;84(5):519-24.

PMID:
10482148
15.
16.

[The FINESSE trial].

Petronio AS, Piscione F.

G Ital Cardiol (Rome). 2009 Jan;10(1):1-5. Italian. No abstract available.

PMID:
19292014
17.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Eur Heart J. 1998 Apr;19 Suppl D:D10-21. Review.

PMID:
9597518
19.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

20.

Supplemental Content

Support Center